221 related articles for article (PubMed ID: 25063884)
1. Monoclonal antibody targeting chikungunya virus envelope 1 protein inhibits virus release.
Masrinoul P; Puiprom O; Tanaka A; Kuwahara M; Chaichana P; Ikuta K; Ramasoota P; Okabayashi T
Virology; 2014 Sep; 464-465():111-117. PubMed ID: 25063884
[TBL] [Abstract][Full Text] [Related]
2. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
[TBL] [Abstract][Full Text] [Related]
3. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
[TBL] [Abstract][Full Text] [Related]
4. Suramin Inhibits Chikungunya Virus Entry and Transmission.
Ho YJ; Wang YM; Lu JW; Wu TY; Lin LI; Kuo SC; Lin CC
PLoS One; 2015; 10(7):e0133511. PubMed ID: 26208101
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of Chikungunya virus inhibition by monoclonal antibodies.
Zhou QF; Fox JM; Earnest JT; Ng TS; Kim AS; Fibriansah G; Kostyuchenko VA; Shi J; Shu B; Diamond MS; Lok SM
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27637-27645. PubMed ID: 33087569
[TBL] [Abstract][Full Text] [Related]
6. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.
Smith SA; Silva LA; Fox JM; Flyak AI; Kose N; Sapparapu G; Khomandiak S; Ashbrook AW; Kahle KM; Fong RH; Swayne S; Doranz BJ; McGee CE; Heise MT; Pal P; Brien JD; Austin SK; Diamond MS; Dermody TS; Crowe JE
Cell Host Microbe; 2015 Jul; 18(1):86-95. PubMed ID: 26159721
[TBL] [Abstract][Full Text] [Related]
7. Serotonergic Drugs Inhibit Chikungunya Virus Infection at Different Stages of the Cell Entry Pathway.
Bouma EM; van de Pol DPI; Sanders ID; Rodenhuis-Zybert IA; Smit JM
J Virol; 2020 Jun; 94(13):. PubMed ID: 32321803
[TBL] [Abstract][Full Text] [Related]
8. Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry.
Henß L; Beck S; Weidner T; Biedenkopf N; Sliva K; Weber C; Becker S; Schnierle BS
Virol J; 2016 Aug; 13(1):149. PubMed ID: 27581733
[TBL] [Abstract][Full Text] [Related]
9. Development of a Specific CHIKV-E2 Monoclonal Antibody for Chikungunya Diagnosis.
Kim J; Yang J; Kim YB; Lee HJ; Kim S; Poo H
Virol Sin; 2019 Oct; 34(5):563-571. PubMed ID: 31214999
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model.
Goh LY; Hobson-Peters J; Prow NA; Gardner J; Bielefeldt-Ohmann H; Pyke AT; Suhrbier A; Hall RA
Clin Immunol; 2013 Dec; 149(3):487-97. PubMed ID: 24239837
[TBL] [Abstract][Full Text] [Related]
11. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease.
Selvarajah S; Sexton NR; Kahle KM; Fong RH; Mattia KA; Gardner J; Lu K; Liss NM; Salvador B; Tucker DF; Barnes T; Mabila M; Zhou X; Rossini G; Rucker JB; Sanders DA; Suhrbier A; Sambri V; Michault A; Muench MO; Doranz BJ; Simmons G
PLoS Negl Trop Dis; 2013; 7(9):e2423. PubMed ID: 24069479
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of monoclonal antibody against non-structural protein-2 of Chikungunya virus and its application.
Chattopadhyay S; Kumar A; Mamidi P; Nayak TK; Das I; Chhatai J; Basantray I; Bramha U; Maiti PK; Singh S; Suryawanshi AR; Chattopadhyay S
J Virol Methods; 2014 Apr; 199():86-94. PubMed ID: 24462973
[TBL] [Abstract][Full Text] [Related]
13. A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.
Weber C; Büchner SM; Schnierle BS
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003684. PubMed ID: 25905779
[TBL] [Abstract][Full Text] [Related]
14. Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence.
Hawman DW; Fox JM; Ashbrook AW; May NA; Schroeder KMS; Torres RM; Crowe JE; Dermody TS; Diamond MS; Morrison TE
Cell Rep; 2016 Aug; 16(5):1326-1338. PubMed ID: 27452455
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of combination treatment using EGCG and suramin against the chikungunya virus.
Lu JW; Hsieh PS; Lin CC; Hu MK; Huang SM; Wang YM; Liang CY; Gong Z; Ho YJ
Biochem Biophys Res Commun; 2017 Sep; 491(3):595-602. PubMed ID: 28760340
[TBL] [Abstract][Full Text] [Related]
16. Western Blot Detection of Human Anti-Chikungunya Virus Antibody with Recombinant Envelope 2 Protein.
Yang Z; Lee J; Ahn HJ; Chong CK; Dias RF; Nam HW
Korean J Parasitol; 2016 Apr; 54(2):239-41. PubMed ID: 27180586
[TBL] [Abstract][Full Text] [Related]
17. Suramin Inhibits Chikungunya Virus Replication by Interacting with Virions and Blocking the Early Steps of Infection.
Albulescu IC; White-Scholten L; Tas A; Hoornweg TE; Ferla S; Kovacikova K; Smit JM; Brancale A; Snijder EJ; van Hemert MJ
Viruses; 2020 Mar; 12(3):. PubMed ID: 32191995
[TBL] [Abstract][Full Text] [Related]
18. Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins.
Quiroz JA; Malonis RJ; Thackray LB; Cohen CA; Pallesen J; Jangra RK; Brown RS; Hofmann D; Holtsberg FW; Shulenin S; Nyakatura EK; Durnell LA; Rayannavar V; Daily JP; Ward AB; Aman MJ; Dye JM; Chandran K; Diamond MS; Kielian M; Lai JR
PLoS Pathog; 2019 Nov; 15(11):e1008061. PubMed ID: 31697791
[TBL] [Abstract][Full Text] [Related]
19. Chikungunya Virus and Its Envelope Protein E2 Induce Hyperalgesia in Mice: Inhibition by Anti-E2 Monoclonal Antibodies and by Targeting TRPV1.
Segato-Vendrameto CZ; Zanluca C; Zucoloto AZ; Zaninelli TH; Bertozzi MM; Saraiva-Santos T; Ferraz CR; Staurengo-Ferrari L; Badaro-Garcia S; Manchope MF; Dionisio AM; Pinho-Ribeiro FA; Borghi SM; Mosimann ALP; Casagrande R; Bordignon J; Fattori V; Santos CNDD; Verri WA
Cells; 2023 Feb; 12(4):. PubMed ID: 36831223
[TBL] [Abstract][Full Text] [Related]
20. Mefenamic acid in combination with ribavirin shows significant effects in reducing chikungunya virus infection in vitro and in vivo.
Rothan HA; Bahrani H; Abdulrahman AY; Mohamed Z; Teoh TC; Othman S; Rashid NN; Rahman NA; Yusof R
Antiviral Res; 2016 Mar; 127():50-6. PubMed ID: 26794398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
